logo
Plus   Neg
Share
Email

WPP H1 Headline Profit Declines; LFL Revenue Less Pass-through Costs Down 2.0%

WPP Group plc (WPP.L,WPPGY) said its first-half reported profit before tax declined 44% driven primarily by a significant prior year first half exceptional gain that has not been repeated and a charge on the revaluation of financial instruments versus a credit in 2018. The company reiterated its 2019 guidance.

For the first-half, reported profit before tax was 478 million pounds compared to 846 million pounds, prior year. Reported earnings per share was 24.8 pence compared to 53.4 pence. Headline profit before tax was down 17.6% to 605 million pounds from 735 million pounds, last year, and down 18.4% in constant currency. Headline earnings per share was 34.2 pence compared to 42.6 pence. Headline operating margin was 11.9%, down 1.2 margin points like-for-like, for the period.

First-half reported revenue was up 1.6% at 7.6 billion pounds. Revenue on a constant currency basis was flat compared with last year. Like-for-like revenue less pass-through costs were down 2.0%, for the period. Reported billings were down 0.5% at 26.5 billion pounds, and down 2.0% in constant currency.

For 2019, the Group continues to project: like-for-like revenue less pass-through costs down 1.5% to 2.0%; and headline operating margin to revenue less pass-through costs down around 1.0 margin point on a constant currency basis.

The Board declared an interim dividend of 22.7 pence per share, the same as last year. The record date for the interim dividend is 4 October 2019, payable on 4 November 2019.

Also, WPP appointed Jasmine Whitbread to its Board as a non-executive director, effective from 1 September 2019. She is currently Chief Executive of London First and a non-executive director of Standard Chartered plc and BT Group plc.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
India-based Lupin Pharmaceuticals Inc. announced a recall of all batches of type 2 diabetes medication Metformin Hydrochloride Extended-Release Tablets, citing detection of N-Nitrosodimethylamine or NDMA, a probable human carcinogen. The move comes after many other drug companies called back Metformin tablets after the U.S. Food and Drug Administration or FDA recommended over NDMA concerns. Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said that the current state of the COVID-19 pandemic in the U.S. is "really not good." The U.S. is the country worst-affected by the coronavirus and has recently seen a surge in coronavirus infections as lockdown restrictions are eased. Granules Pharmaceuticals, Inc. recalled twelve (12) lots of type 2 diabetes medication Metformin hydrochloride Extended-Release, in the form of oral film-coated tablets, for the potential presence of nitrosamine impurity, N-Nitrosodimethylamine (NDMA), above levels of the Acceptable Daily Intake Limit (ADI), the U.S. Food and Drug Administration or FDA said in a statement.
RELATED NEWS
Follow RTT